Quince Therapeutics (NASDAQ:QNCX) Rating Lowered to “Market Perform” at Citizens Jmp

Quince Therapeutics (NASDAQ:QNCX) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday.

Other equities research analysts have also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Quince Therapeutics in a research note on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quince Therapeutics in a research report on Monday, December 29th. Finally, Citigroup downgraded shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Quince Therapeutics currently has an average rating of “Hold” and an average target price of $8.00.

Quince Therapeutics Stock Performance

NASDAQ:QNCX opened at $0.27 on Friday. Quince Therapeutics has a 52 week low of $0.23 and a 52 week high of $4.55. The firm’s fifty day moving average is $3.29 and its 200-day moving average is $2.26. The firm has a market cap of $15.03 million, a P/E ratio of -0.22 and a beta of 1.15.

Quince Therapeutics (NASDAQ:QNCX) last released its earnings results on Wednesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.05). As a group, sell-side analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC acquired a new stake in shares of Quince Therapeutics in the 2nd quarter worth about $4,172,000. Millennium Management LLC raised its stake in shares of Quince Therapeutics by 1,152.9% in the third quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after purchasing an additional 1,276,094 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Quince Therapeutics by 442.1% in the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock valued at $1,263,000 after purchasing an additional 632,076 shares in the last quarter. Almitas Capital LLC purchased a new position in shares of Quince Therapeutics during the third quarter valued at approximately $806,000. Finally, Vanguard Group Inc. grew its holdings in Quince Therapeutics by 21.3% during the third quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock worth $2,874,000 after buying an additional 309,349 shares in the last quarter. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Key Quince Therapeutics News

Here are the key news stories impacting Quince Therapeutics this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and a $5.00 price target, signaling at least one analyst sees upside if the company can redeploy assets or secure new programs. Analyst Note
• Neutral Sentiment: Quince presented previously published long‑term safety data for eDSP at the British Paediatric Neurology Association meeting on Jan. 28 — useful context on tolerability but not sufficient to sustain the program after the Phase 3 outcome. Safety Data Presentation
• Neutral Sentiment: Trading was repeatedly halted late in the session (multiple LULD pauses and a “News pending” halt) as the market awaited and then digested the company’s Phase 3 announcement; these halts magnified intraday volatility.
• Negative Sentiment: Topline Phase 3 results were reported as negative, and Quince said it is ending development of eDSP — eliminating the company’s lead program and near‑term path to revenue. This is the primary reason for the steep share decline. Phase 3 Failure Report
• Negative Sentiment: Market commentary and press coverage emphasize the program termination and the stock’s >90% intraday drop; investors should expect severe dilution risk, limited near‑term pipeline value, and possible questions about the company’s cash runway and strategic alternatives. Program Termination Coverage
• Negative Sentiment: News aggregators and health outlets summarized why QNCX collapsed today — reinforcing negative sentiment and reducing likelihood of a quick rebound absent new assets, financing, or a strategic transaction. Market Reaction Summary

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.